Swedish site will participate in the Foxy-5 phase 1b study
WntResearch today announces that the Department of Oncology and the Clinical Trial Unit (Phase I), R&D Centre, Skåne University Hospital Lund have agreed to participate as a site in the clinical phase 1b study with Foxy-5. The phase 1b study will be initiated as soon as the study application has been approved (see press release 2015-12-14). Nils Brünner, CEO: “We are very happy to extend the number of clinical sites for the upcoming phase 1b study with a Swedish site. This ought to result in a more efficient recruitment of patients into the study.” For additional information please